Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report

Author： Nygren Peter   Sørbye Halfdan   Österlund Pia   Pfeiffer Per  

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.44, Iss.3, 2005-05, pp. : 203-217

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer

By Larsen Finn Ole   Pfeiffer Per   Nielsen Dorte   Skougaard Kristin   Qvortrup Camilla   Vistisen Kirsten   Fromm Anne-Lene   Jøørgensen Trine L.   Bjerregaard Jon K.   Hoegdall Estrid   Jensen Benny V.  

Acta Oncologica, Vol. 50, Iss. 4, 2011-05 ,pp. : 574-577

Informa Healthcare

Access to resources Recommend Favorite

Cetuximab as salvage monotherapy in chemotherapyrefractory metastatic colorectal cancer: A singlecenter report

By                          

Oncology Letters, Vol. 6, Iss. 4, 2013-01 ,pp. : 1011-1014

Spandidos Publications

Access to resources Recommend Favorite

Bevacizumab in the treatment of metastatic colorectal cancer

By Caprioni Francesco   Fornarini Giuseppe  

Future Oncology, Vol. 3, Iss. 2, 2007-04 ,pp. : 141-148

Future Medicine

Access to resources Recommend Favorite

How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?

By Lindsay Colin R   Roxburgh Patricia   Graham Janet  

Future Oncology, Vol. 9, Iss. 6, 2013-06 ,pp. : 825-829

Future Medicine

Access to resources Recommend Favorite

Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma

By          

Oncology Letters, Vol. 5, Iss. 2, 2013-01 ,pp. : 637-640

Spandidos Publications

Access to resources Recommend Favorite